Galera Therapeutics Inc expected to post a loss of 44 cents a share - Earnings Preview

Galera Therapeutics

04/08/2023 19:32

* Galera Therapeutics Inc  GRTX.OQ   GRTX.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 7 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Galera Therapeutics
Inc
is for a loss of 44 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Galera
Therapeutics Inc is $6.5​, above​ its last closing price
of $2.23. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.42       -0.38      -0.50     Missed  -30.8
 Dec. 31 2023  -0.54       -0.54      -0.58     Missed  -8
 Sep. 30 2022  -0.50       -0.52      -0.60     Missed  -14.3​
 Jun. 30 2022  -0.52       -0.53      -0.54     Missed  -2.4
 ​​Mar.        -0.57       -0.57      -0.58     Missed  -1.5
 31 2022                                                
 Dec. 31 2021  -0.74       -0.75      -0.64     Beat    14.7​
 Sep. 30 2021  -0.78       -0.77      -0.86     Missed  -12.4
 Jun. 30 2021  -0.81       -0.83      -0.88     Missed  -6.2
 This summary was machine generated August 4 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated